Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT
Natera, Inc. (NTRA)
Last natera, inc. earnings: 2/26 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.natera.com
Company Research
Source: Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and precision medicine, today announced it will expand its Fetal Focus test to cover 20 genes, marking a major advancement in single-gene noninvasive prenatal testing (sgNIPT). Building on the success of the initial Fetal Focus 5-gene test, launched in August, the new expanded panel will launch in Q4 2025.Fetal Focus’ unique approach, using Natera’s proprietary LinkedSNP™ technology, is optimized to detect challenging homozygous cases where the fetus inherits two copies of the same mutation from both parents. Since the product launch, Fetal Focus has already identified a pregnancy affected with cystic fibrosis that was homozygous for the delta F508 mutation and missed by another laboratory. While this case highlights the utility of Natera’s LinkedSNP technology, clinical performance of genetic tests should be rigorously established in prospective, well-designed clinical studies.In
Show less
Read more
Impact Snapshot
Event Time:
NTRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTRA alerts
High impacting Natera, Inc. news events
Weekly update
A roundup of the hottest topics
NTRA
News
- New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual MeetingBusiness Wire
- Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer SymposiumBusiness Wire
- Natera (NASDAQ:NTRA) was given a new $265.00 price target on by analysts at Morgan Stanley.MarketBeat
- Natera (NASDAQ:NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $240.00 to $250.00. They now have an "overweight" rating on the stock.MarketBeat
- Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer MonthBusiness Wire
NTRA
Earnings
- 11/6/25 - Miss
NTRA
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- NTRA's page on the SEC website